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Background
The reasons for the recent failure of the Merck STEP trial,
wherein Ad5-seropositive subjects demonstrated
increased susceptibility to HIV infection, remain unclear.
One potential hypothesis is that expansion and mucosal
trafficking of Ad5-specific CD4+ T cells following Ad-vec-
tor immunization possibly rendered vaccinees more sus-
ceptible to HIV infection.
Methods
Ad-specific T cell responses were characterized in five sero-
positive and seronegative subjects from the Merck phase I
016 trial, the immediate STEP trial predecessor. Subjects
received 3 × 1011 vector particles Merck Ad5 gag/pol/nef
at weeks 0, 4 and 30. PBMC samples were obtained at
weeks 0, 4, 8,18, 26, 30, 42, 52 and 78 relative to vaccina-
tion. T-cell responses to Ad were measured by stimulating
PBMCs overnight with whole Ad vector before measuring
functionality (IFN-γ, TNF-α, IL-2) memory phenotype
(CD45RO, CCR7) and mucosal homing markers (α4, β7,
CCR10, αE) by multicolor flow cytometry.
Results
There was no difference in the % of total or Ad-specific
α4+β7+ CD4+ T-cells between seronpositive and seroneg-
ative subjects. There was also no increase in total or Ad-
specific α4+β7+ CD4+ T-cells following vaccination. Ad-
specific CD4+ T-cells comprised only 1–2% of total
α4+β7+ cells in the blood. The memory phenotype of
α4+β7+ was mixed between central memory, effector
memory and effector CD4+ T-cells in both serogroups
with no change in memory phenotype observed upon
vaccination. CCR10 and CD103 were expressed at mar-
ginal levels on Ad-specific CD4+ T cells.
Conclusion
This data suggests that vaccination does not induce a dif-
ferential measurable effect on mucosal trafficking in circu-
lating Ad-specific CD4+ T cells between the serogroups
and therefore contradicts a role for Ad-specific T-cells in
the possible increased risk of HIV infection observed dur-
ing the STEP trial.
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